PRM 167

Drug Profile

PRM 167

Latest Information Update: 21 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Promedior
  • Class Anti-inflammatories; Antifibrotics; Glycoproteins; Recombinant proteins
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Retinal disorders

Most Recent Events

  • 21 Oct 2016 Preclinical development is ongoing for Age-related macular degeneration and Retinal disorders in USA (Promedior pipeline, October 2016)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intravitreous)
  • 31 Aug 2015 Promedior and Bristol Myers Squibb enter an agreement that grants Bristol Myers Squibb exclusive right to acquire Promedior
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top